3 March 2023
Sidley Represents Keymed Biosciences in US$1.1 Billion Partnership With AstraZeneca and Lepu Biopharma
Advising firms
Deal team
13 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| James Lu Lead | Sidley | Not stated | Emerging Companies and Venture Capital | Not stated |
| Stephen Abreu Lead | Sidley | Not stated | Not stated | Not stated |
| Longbo Wang Lead | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Ed Sharon Lead | Sidley | Not stated | Antitrust/Competition | Not stated |
| Cassidy A. Pomeroy-Carter | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| Ashleigh Lussenden | Sidley | Not stated | Technology and Life Sciences Transactions | Not stated |
| William Blumenthal | Sidley | Not stated | Antitrust/Competition | Not stated |
| Jason C. Semmes | Sidley | Not stated | Antitrust/Competition | Not stated |
| Oliver Zhong | Sidley | Not stated | Capital Markets | Not stated |
| Emma Ballard | Sidley | Not stated | Commercial Litigation and Disputes | Not stated |
| Scott Nonaka | Sidley | Not stated | Global Arbitration, Trade and Advocacy | Not stated |
| Cynthia Bai | Sidley | Not stated | Global Finance | Not stated |
| Pan Chen | Sidley | Not stated | M&A | Not stated |
Stated terms
- Stated value
- USD 1.10bn (US$1.1 billion)
- What the figure measures
- Total transaction value
- Client
- Keymed BiosciencesSell-side
- Counterparties
- AstraZeneca (Buy-side)
Lepu Biopharma (Joint venture party)